Absorption of omega-3 Nutritional, Metabolic, Endocrine
Conditions
Interventions
Randomisation will be conducted by someone not involved in the conduct of the trial. The randomisation code for the IP will be generated by Random Allocation Software. The product will be randomised
Sponsors
dsm-firmenich Switzerland AG
RDC Global
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Written informed consent obtained before any trial related assessments are performed 2. Healthy adult females ages 18-64 years who are neither pregnant nor breastfeeding or healthy adult males aged 18-64 years at the time of consent Female participants of child-bearing potential (females who are postmenopausal, i.e., when there has been no menstruation for a minimum of 12 months prior to screening, are considered not to be of childbearing potential), who are not surgically sterilized, must have a negative pregnancy test at screening and be willing to practice one of the following appropriate contraceptive methods until the last visit: 2.1. Sexual abstinence 2.2. Oral contraceptives 2.3. Transdermal patches or depot injection of a progestogen drug (starting at least 4 weeks prior to product administration) 2.4. Intrauterine device (IUD), intrauterine system (IUS), subdermal implant, or vaginal ring (placed at least 4 weeks prior to product administration) 2.5. Contraceptives must be effective before the randomization visit 3. Participant’s body mass index (BMI) must be between 18 and 30 kg/m2 (inclusive) and participant must weigh a minimum of 50 kg (110 lbs) 4. Intakes of EPA+DHA of <200 mg per day based on the FFQ 5. Agree not to change current diet and exercise frequency or intensity during entire study period
Exclusion criteria
Exclusion criteria: 1. Participant has any health conditions that would prevent from fulfilling the study requirements, put the participant at risk or would confound the interpretation of the study results as judged by the Investigator based on medical history and routine laboratory test results. 2. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results. 3. Has a clinically significant abnormal finding on the medical assessment, medical history, vital signs or clinical laboratory results at screening. 4. History or presence of allergic or adverse response to omega-3-acid ethyl esters or triglycerides (EPA or DHA), or related drugs, or sensitivity or allergy to fish or shellfish, or soybean or corn. 5. History of coagulation disorder or current anticoagulation therapy. 6. Has been on a significantly abnormal* diet, as deemed by the investigator, during the 4 weeks preceding the first dose of study medication. *an abnormal diet will be considered if the participant has elected to change to a more or less restricted diet of any description (e.g., change to or from a vegetarian, vegan, gluten-free, lactose-free, etc.) or significantly increases or decreases their daily caloric intake. 7. Has participated in another clinical trial (randomised participants only) within 30 days prior to the first dose of study medication. 8. Has used prescription medication (excluding oral contraceptive and hormonal replacement therapy) within 4 weeks of screening or OTC medication within 7 days before the first dose that may affect omega-3 absorption or any study outcomes. This may include but is not limited to: high-dose NSAIDs, bile acid sequestrants, statins, GLP-1 receptor agonists, anticoagulants and anti-inflammatory drugs. Occasional ibuprofen, paracetamol and low-dose aspirin use is permitted. 9. Regular use* of omega-3 supplements and/or regular fatty fish consumption within 2 months. *Regular use is defined as more than once per week of either fish oil, krill oil, microalgal oil supplements, or fatty fish. 10. Has smoked or used tobacco products within 60 days prior to the first dose of study medication. 11. History of substance abuse or treatment (including more than 14 alcoholic drinks per week) within the past 2 years based on the judgement of the investigator. 12. Has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates). 13. Has increased bleeding from existing pathological conditions or anticipates surgery (including dental) prior to, throughout, or within 1 week after study participation. 14. Has had a transient ischemic attack (TIA) or stroke or is at high risk for recurrent ischemic events
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma phospholipids EPA+DHA µg/ml levels determined by gas chromatography (GC) from baseline to week 6 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Plasma phospholipids EPA+DHA µg/ml levels determined by gas chromatography (GC) from baseline to weeks 2, 4, and 6 2. Omega-3 Index (percent of EPA + DHA in red blood cell membranes) determined by gas chromatography (GC) from baseline to week 6 3. Plasma phospholipids EPA+DHA µg/ml levels determined by gas chromatography (GC) from baseline to weeks 2 and 4 4. Total cholesterol, HDL- and LDL-cholesterol and triglyceride levels determined by a clinical analyser from baseline to week 6 | — |
Countries
Australia
Contacts
Public ContactChantal Ferris-Hayes
Outcome results
None listed